A new National Academies report recommends ways for the U.S. to reap the benefits of artificial intelligence in biotechnology ...
The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.
BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.
Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...
Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...
In essence, the future of AI is inextricably linked to advancements in data management, making it an indispensable enabler of ...
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
The collaboration will leverage Nosis’ Connexa™ platform, an advanced AI-powered drug design and delivery system, to enable therapeutic access to extrahepatic cell types across multiple vital ...
13d
GlobalData on MSNNovo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic dealNovo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...
5d
GlobalData on MSNElevateBio taps Amazon’s genAI tools to design CRISPR therapeuticsAWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results